
Precision Medicine in Oncology®
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News







Amid an explosion of innovation and discovery in the oncology field, researchers are finding it increasingly difficult to recruit enough patients for clinical trials.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of osimertinib as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations.

















Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
3
Latest ACS Cancer Statistics Report Outlines Notable Gains, Remaining Gaps Across Tumor Types
4
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
5




































